Three Growth Stocks to Consider Amid Market Fluctuations

Yo-yos can be entertaining for children, but yo-yo stock markets are frustrating for adult investors. Recently, there has been a noticeable shift, with more down days than up.

Many investors may feel overwhelmed by the market’s rapid changes, particularly influenced by the Trump administration’s inconsistent tariff announcements. However, there are three growth stocks worth considering for purchasing during the market’s rebound.

Where to invest $1,000 right now? Our analyst team has identified the 10 best stocks to buy at this time. Learn More »

1. Amazon

Amazon’s (NASDAQ: AMZN) stock price dropped as much as 29% below its previous high during the recent market downturn. This decline is understandable, considering that tariffs could negatively impact the company’s e-commerce revenue by causing a drop in consumer spending. Yet, I argue that Amazon might be better insulated from economic challenges than many believe.

One reason for this resilience is that consumers are likely to rely on Amazon, even more, during economic struggles. The platform offers low prices on a vast range of products. In fact, independent market research from Profitero has recognized Amazon as the lowest-priced online retailer in the U.S. for eight consecutive years.

Furthermore, Amazon is well-positioned to benefit from ongoing advancements in artificial intelligence (AI), especially generative AI. Most AI applications are hosted in the cloud, and as the largest provider of cloud services, Amazon Web Services (AWS) is set to achieve significant growth, irrespective of external market pressures.

AI is not only a growth factor for AWS. Amazon has a chance to take the lead in the emerging field of AI personal assistants. The application of AI technology is also boosting efficiency and profitability in Amazon’s other business sectors. Historically, purchasing Amazon shares on price dips has rewarded investors, and I anticipate the trend will continue.

2. Meta Platforms

The stock trajectory of Meta Platforms (NASDAQ: META) has mirrored that of Amazon. The reasons for considering an investment in Meta also closely align with those for Amazon.

Facebook, Instagram, Messenger, and WhatsApp collectively attract an average of 3.35 billion users daily, representing over 40% of the global population. While advertising revenue on these platforms may decline slightly during an economic downturn, Meta’s vast audience makes it hard for advertisers to ignore. I expect that the company will continue to generate billions in revenue and profits, regardless of overall economic conditions.

Although Meta doesn’t operate as a cloud service provider like Amazon, it stands to gain significantly from AI developments. The technology plays a crucial role in enhancing the monetization capabilities of Meta’s platforms. Moreover, Meta is utilizing generative AI to aid advertisers in creating campaigns more efficiently and rapidly.

According to CEO Mark Zuckerberg, Meta AI is “already used by more people than any other [AI] assistant.” He forecasts that over 1 billion people will use AI assistants by 2025, positioning Meta AI as a potential market leader. He also hinted that we may discover this year whether AI smart glasses will become “the next computing platform.” If that prediction holds, then Meta stock could see substantial future gains.

3. Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ: VRTX) stock has remained relatively resilient amid market volatility. Although it did experience a slight decline, it has since partially rebounded, presenting an attractive buying opportunity.

One significant reason for my optimism about Vertex in the near term is the rollout of its new pain medication, Journavx. It notably alleviates acute pain without being an opioid, which opens up a considerable market for a safe and effective non-opioid painkiller.

Additionally, I am interested in Vertex’s latest cystic fibrosis (CF) treatment, Alyftrek, which received approval from U.S. regulators in December 2024. While Alyftrek might cannibalize sales from Vertex’s existing CF drugs, it is expected to be more profitable due to lower royalty obligations.

Vertex’s gene-editing therapy, Casgevy, could gradually increase sales as it serves as a one-and-done solution for conditions like sickle cell disease and transfusion-dependent beta-thalassemia. Plus, Vertex boasts a promising development pipeline containing four late-stage programs with significant commercial potential. Consequently, I predict this stock will yield solid returns in the coming years, regardless of economic fluctuations or tariffs.

Should you invest $1,000 in Vertex Pharmaceuticals right now?

Before deciding to buy stock in Vertex Pharmaceuticals, consider the following:

The Motley Fool Stock Advisor analyst team has revealed the 10 best stocks for investors to consider now, and Vertex Pharmaceuticals did not make this list. The selections that were highlighted have strong potential for generating substantial returns in the coming years.

For example, consider when Netflix made this list on December 17, 2004… with a $1,000 investment at that time, you’d have $495,226!*

Furthermore, Nvidia joined the list on April 15, 2005… if you had invested $1,000 then, you’d now have $679,900!*

It’s important to note that Stock Advisor has delivered a total average return of 796%, significantly outperforming 155% for the S&P 500. Don’t miss out on the latest top 10 list available when you subscribe to Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 14, 2025

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, sits on The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is also a board member. Keith Speights has holdings in Amazon, Meta Platforms, and Vertex Pharmaceuticals. The Motley Fool holds positions in and recommends Amazon, Meta Platforms, and Vertex Pharmaceuticals. More information on the disclosure policy is available.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.